Dashboard
Company has a low Debt to Equity ratio (avg) at times
Healthy long term growth as Operating profit has grown by an annual rate 21.02%
The company has declared negative results in Mar'2025 after 7 consecutive positive quarters
With ROE of 9.19%, it has a very expensive valuation with a 2.09 Price to Book Value
High Institutional Holdings at 100%
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
USD 2,105 Million (Small Cap)
23.00
NA
0.00%
0.09
9.34%
2.06
Total Returns (Price + Dividend) 
Addus HomeCare Corp. for the last several years.
Risk Adjusted Returns v/s 
News

Addus HomeCare Forms Golden Cross, Signaling Potential Bullish Breakout
Addus HomeCare Corp. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock has shown positive short-term performance, gaining 1.88% today and 8.08% over the past week, despite a one-year decline. Mixed technical indicators suggest varying market sentiment as the company moves forward.
Read MoreIs Addus HomeCare Corp. technically bullish or bearish?
As of 12 September 2025, the technical trend for Addus HomeCare Corp. has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. The weekly MACD is bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are bearish, and both the weekly and monthly KST and OBV are mildly bearish. The Bollinger Bands show a sideways trend weekly but are bearish monthly. In terms of performance, Addus HomeCare has underperformed the S&P 500 across multiple periods, with a year-to-date return of -12.40% compared to the S&P 500's 12.22%, and a one-year return of -17.14% against the S&P 500's 17.14%....
Read MoreIs Addus HomeCare Corp. overvalued or undervalued?
As of 4 August 2025, Addus HomeCare Corp. has moved from an attractive to a fair valuation grade. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 23, an EV to EBITDA of 16.07, and a PEG ratio of 1.38, which suggest that the stock is priced in line with its earnings growth expectations. In comparison to its peers, Addus HomeCare Corp. has a P/E ratio of 22.05, while The Ensign Group, Inc. is rated attractive with a significantly higher P/E of 32.46, indicating that Addus may not be as richly valued as some competitors. Additionally, U.S. Physical Therapy, Inc. also shows a fair valuation with a P/E of 28.81, further supporting the notion that Addus is neither undervalued nor overvalued in its sector. Over the past year, Addus HomeCare Corp. has underperformed the S&P 500, returning -17.14% compared to the index's 17.14%, reinforcing the view that the s...
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 98 Schemes (50.21%)
Held by 126 Foreign Institutions (7.89%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 21.78% vs 10.35% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 22.10% vs 21.48% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 9.06% vs 11.31% in Dec 2023
YoY Growth in year ended Dec 2024 is 17.76% vs 35.87% in Dec 2023






